TheLife Sciencesteam represented Inozyme Pharma, Inc. in a definitive agreement to be acquired by BioMarin Pharmaceutical Inc. for $4.00 per share in an all-cash transaction for a total consideration of approximately $270 million. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2025, subject to regulatory approval, successful completion of a tender offer and other customary closing conditions. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones.
Inozyme Pharmais a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, the company aims to transform treatment options for patients affected by these devastating conditions.
The Goodwin team was led byRachael Bushey,Jennifer Porter,Laura Gulick,Nathalie Dabrowski, andAndrea Akinbolaand includedKrisn Modi,Iris Zike,Madeline Linder,Caroline Bullerjahn,Christina Ademola,Arman Oruc,Kevin Walsh,Sarah Bock,Eric Graffeo,Daniel Scolnick,Alicia Palladino,Susan Lee,Carrie Clowney,Dan Karelitz,Tyler Mayo,Christina Lewis,Ana Alvarado,Jacqueline Klosek,Omer Tene,Richard MathenyandGozde Guckaya.
For more information on the deal, please read thepress releaseand coverage inEndpoints News.